AbbVie just rewarded its shareholders again with a dividend. This stock has boosted its payout annually for more than 50 ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a preclinical-stage, oral drug for psoriasis. US-based Nimble was set up in ...
Dividend-growth stocks offer steady income and long-term value. With the Fed holding rates and inflation expected to ease, ...
AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...
AbbVie’s Cancer Deal With Xilio Therapeutics AbbVie announced a collaboration and option agreement with cancer biotech Xilio Therapeutics to develop novel immunotherapies, including masked T ...
Learn More » AbbVie is recognized as a leading drugmaker with an extensive portfolio of therapeutics in fields such as immunology, oncology, neuroscience, and eye care. Additionally, the company ...
AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...
AbbVie (ABBV) announced that its board of directors has unanimously elected CEO Robert Michael to assume the additional position of chairman, effective July 1. He will succeed Richard Gonzalez ...
For the recent deal, Novartis will make an upfront payment of $925 million to Anthos Therapeutics, with the latter also being entitled to receive up to approximately $2.15 billion in potential ...